Florida is currently home to 3751 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Recruiting
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida
Conditions: Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, Recurrent Glioma
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
Recruiting
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia
Gender:
ALL
Ages:
11 years and below
Trial Updated:
03/26/2025
Locations: UF Health Pediatric Multispecialty Center, Jacksonville, Florida
Conditions: Hyperkalemia
A Retrospective Assessment of OviTex PRS (OviTex)
Recruiting
The objective of this retrospective-prospective, observational study is to evaluate the safety profile overall and within two device types of OviTex PRS in previous pre-pectoral or sub-pectoral implant-based breast reconstructions.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Aesthetic Surgery Center, Naples, Florida
Conditions: Reconstructive Surgical Procedures
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/26/2025
Locations: Brain Matters Research, Delray Beach, Florida
Conditions: Early Alzheimer's Disease
Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates
Recruiting
To examine the effectiveness of an individual health coaching intervention for lung transplant candidates. This intervention will include up to 12 health coaching sessions via phone call over a 12-16 week period. This will be compared to a usual care group the receives pre-transplant care and education alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Lung Transplant
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/26/2025
Locations: Prestige Clinical Research Center, Inc., Coral Gables, Florida
Conditions: Schizophrenia
GEMINI-NSCLC: NSCLC Biomarker Study
Recruiting
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Clermont Oncology Center, Clermont, Florida
Conditions: Non-Small Cell Lung Cancer
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Recruiting
The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Squamous Cell Carcinoma
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
Recruiting
This phase Ib trial evaluates the best dose, potential benefits, and/or side effects of erdafitinib in combination with enfortumab vedotin in treating patients with bladder cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and possesses genetic alterations in FGFR2/3 genes. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage IV Urethral Cancer AJCC v8, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
Recruiting
This study is a Phase I/II study evaluating the safety and effectiveness of focused radiation therapy (radiosurgery) together with olaparib, followed by immunotherapy, for patients with brain metastases from triple negative or BRCA-mutated breast cancers. This study will have a Phase I portion in which subjects will be enrolled based on 3+3 dose escalation rules. Three dose levels of olaparib will be studied. Cycle 1 of study treatment will consist of Olaparib given twice daily concurrently wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Memorial Healthcare System, Hollywood, Florida
Conditions: Breast Cancer, Brain Metastases, Adult
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Recruiting
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/26/2025
Locations: Arnold Palmer Hospital for Children - The Haley Center for Children's Cancer and Blood Disorders, Orlando, Florida
Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration
Recruiting
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD)
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/26/2025
Locations: Retina Specialty Institute, Pensacola, Florida
Conditions: Macular Degeneration